Recent Transactions

29-May-07
$99.1 billion
Netherlands flag
Target: 

ABN AMRO Holding NV

U.K., Spain, Belgium flags
Acquiror: 
Fortis SA/NV, The Royal Bank of Scotland Group plc, Banco Santander Central Hispano, SA

Advised Fortis on an offer by Fortis, RBS and Santander for ABN AMRO

12-Mar-09
$46.9 billion
United States flag
Target: 

Genentech, Inc.

Switzerland flag
Acquiror: 
Roche Holding Ltd.

Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company

18-Feb-14
$25.1 billion
United States flag
Target: 

Forest Laboratories Inc.

Ireland flag
Acquiror: 
Actavis plc

Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.

24-Mar-06
$21.2 billion
Germany flag
Target: 

Schering AG

Germany flag
Acquiror: 
Bayer AG

Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany

27-Mar-18
$13.0 billion
Switzerland flag
Target: 

Novartis AG’s 36.5% stake in Consumer Health Joint Venture

United Kingdom flag
Acquiror: 
GlaxoSmithKline plc

Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture

15-Dec-10
$12.9 billion
U.S.A., Swiss flags
Target: 

Alcon, Inc.

Switzerland flag
Acquiror: 
Novartis AG

Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company

20-May-13
$8.5 billion
Ireland flag
Target: 

Warner Chilcott, plc

United States flag
Acquiror: 
Actavis, Inc.

Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc

01-Aug-12
$4.0 billion
South Africa, Switzerland flags
Target: 

Mediclinic International Limited

Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa

22-Jan-08
$3.4 billion
United States flag
Target: 

Ventana Medical Systems, Inc.

Switzerland flag
Acquiror: 
Roche Holding Ltd.

Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a US based provider of histopathology diagnostic equipment

25-Oct-05
$2.1 billion
Germany flag
Target: 

BHW Holding AG

Germany flag
Acquiror: 
Deutsche Postbank AG

Advised BHW Holding AG, a retail financial services group, in connection with its sale to Deutsche Postbank AG, Germany’s largest retail bank

06-Jul-09
$2.0 billion
Switzerland flag
Target: 

PARIS RE Holdings Ltd.

Bermuda flag
Acquiror: 
PartnerRe Ltd.

Advised PartnerRe Ltd., a leading global reinsurer, providing multi-line reinsurance to insurance companies, on its acquisition of PARIS RE Holdings Ltd., a French-listed, Swiss-based diversified reinsurer

31-Oct-17
$2.0 billion
South Africa, Switzerland flags
Target: 

Hirslanden Private Hospital Group

flag not available

Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt

22-Apr-10
$1.9 billion
United States flag
Target: 

Bank of America Corporation

Euro flag
Acquiror: 
AXA Private Equity

Advised AXA Private Equity, a leading European diversified private equity firm, on the acquisition of a portfolio of limited partnership interests in private equity funds from Bank of America

08-Jun-11
$1.7 billion
United States flag
Target: 

Citigroup (selected private equity assets)

Euro flag
Acquiror: 
AXA Private Equity

Advised AXA Private Equity, a leading European diversified private equity firm, on its acquisition of a $1.7 billion portfolio of limited partnership interests in private equity buyout funds and a portfolio of direct stakes in companies from Citigroup

05-Aug-14
$1.3 billion
U.S.A., Germany flags
Target: 

Siemens Health Services

United States flag
Acquiror: 
Cerner Corporation

Advised Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.

11-Mar-11
$1.0 billion
Russia flag
Target: 

Troika Dialog Group Limited

Russia flag
Acquiror: 
Sberbank

Advised TD Advisors Limited, a major shareholder of Troika Dialog Group, Russia’s leading investment bank, on the sale of their stake as part of the acquisition of Troika Dialog Group by Sberbank, the largest commercial bank in Russia

22-Sep-00
$750 million
Ireland flag
Target: 

AerFi Group plc

Germany flag
Acquiror: 
debis AirFinance (subsidiary of Daimler Chrysler AG)

Advised AerFi on its sale to debis AirFinance .

03-Jan-17
$536 million
U.K., France flags
Target: 

LCH.Clearnet SA

France flag
Acquiror: 
Euronext N.V.

Advised LCH.Clearnet Group Limited, a leading multi-asset class European clearing house, on a sale of LCH.Clearnet SA, its French-regulated operating subsidiary, to Euronext N.V. that was ultimately terminated

20-Dec-06
$424 million
Russia flag
Target: 

Aton Capital

Italy Austria flags
Acquiror: 
Bank Austria Creditanstalt / UniCredit Group

Advised Aton Capital Group, the independent Russian investment bank, on the sale of its Institutional Business to Bank Austria Creditanstalt (part of the UniCredit Group)

09-Nov-09
$327 million
United States flag
Target: 

Enzon Pharmaceuticals, Inc.

Italy flag
Acquiror: 
Sigma-Tau Pharmaceuticals

Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company

02-Feb-16
$314 million
Greece flag
Target: 

11 Private Equity Fund Positions Managed by NBGI Private Equity and Team’s Spinout

U.S.A., U.K. flags
Acquiror: 
Deutsche Bank Private Equity and Goldman Sachs Asset Management

Advised the National Bank of Greece SA, the leading bank in Greece by deposits and total assets, on the disposal of 100% of its interests in eleven funds managed by NBGI Private Equity. The management responsibility of the funds and underlying investments will continue to be performed by the current management team along with other persons appointed by the buyers, under a new management vehicle created expressly for this purpose

22-Jun-05
$198 million
U.K., Switzerland flags
Target: 

Rothschilds Continuation Holdings

Hong Kong flag
Acquiror: 
Jardine Strategic Holdings

held by Royal & Sun Alliance
Advised Royal & Sun Alliance on the sale of its 21.5% shareholding in Rothschilds Continuation Holdings AG to Jardine Strategic Holdings

28-Mar-22
Pending
$105 million
United Kingdom flag
Target: 

Acacia Pharma Group plc

United States flag
Acquiror: 
Eagle Pharmaceuticals, Inc.

Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise

01-Oct-08
$53 million
Sweden flag
Target: 

Biotage (Biosystems division)

Netherlands flag
Acquiror: 
Qiagen NV

Advised Biotage AB (OMX: BIOT), a global biotechnology company, on its strategic review resulting in the disposal of its Biosystems division which offers systems for genetic analysis mainly for use in clinical research

19-Feb-21
$33 million
U.S.A., U.K. flags
Target: 

Acacia Pharma Group plc

flag not available
Acquiror: 
N/A

Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share

Pages

show all